Cell line-derived Xenograft (CDX) Mouse Models

Cell-line derived xenograft (CDX) mouse models represent one of the first steps of determining the efficacy of your novel anticancer therapies in an in vivo model 

Home » Oncology CRO Services » Cell line-derived Xenograft (CDX) Mouse Models

Cell line-derived xenograft (CDX) mouse models are established from immortalized human cancer cells that are implanted and grown in immunodeficient mice. However, to fully recapitulate the intricacies between the immune system and the rodent tumor microenvironment, humanized models are recommended instead of immunodeficient mice. In comparison to syngeneic mouse models, human cell line-derived xenograft (CDX) models offer you the advantage of working with a mouse model with relevant human cancer target proteins as opposed to rodent proteins.  

Therefore, experts at InnoSer recommend the use of CDX models as a first step to evaluate the efficacy of your novel targeted anti-cancer compounds using in vivo models of human cancer. Accordingly, cell line-derived xenograft (CDX) mouse models represent an easy-to-use and relatively inexpensive mouse model with short study timelines (2-4 weeks), offering you a cost-effective alternative to other preclinical screening models. However, for running more advanced studies, InnoSer’s experts recommend performing in vivo studies using patient-derived xenograft (PDX) mouse models, offering you the most clinically relevant in vivo cancer model.

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio. 

Services with cell line-derived xenograft (CDX) mouse models from InnoSer: 

  • Available as subcutaneous, metastatic or orthotopic models (follow-up via ultrasound).  
  • Both murine and rat cell lines are available.  
  • Complementary biodistribution, microenvironment studies and PK/PD profiling services 

Find the right model for you.

Compare our model capabilities and discover which of our oncology platforms suits your research needs

oncology leaflet download

Key cell line-derived xenograft (CDX) mouse model readouts:

Test the efficacy of your treatments with the following readouts:  

  • Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses) 
  • In vivo imaging (bioluminescence imaging, ultrasound)  
  • Isolation of tumors and other relevant organs for histopathology analyses 
  • Blood sampling for biomarker analyses (MSD) 

Related model options

Oncology Platform Overview

Highly relevant oncology CRO services to facilitate preclinical drug development.

Syngeneic Mouse Models

InnoSer offers contract research services using subcutaneous and orthotopic syngeneic mouse models.

Patient-derived Xenograft (PDX) Mouse Models

Recapitulate the tumor and patient heterogeneity using patient-derived xenograft (PDX) mouse models.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

AAALAC logo

Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know